Profile data is unavailable for this security.
About the company
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. The Company’s anti-infective product development portfolio includes three programs, including ATI-1701, ATI-1801 and ATI-1501. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin that affects hundreds of thousands of people around the world annually. The ATI-1501 is a taste-masked liquid oral suspension formulation of the antibiotic metronidazole.
- Revenue in CAD (TTM)827.41k
- Net income in CAD-3.78m
- Incorporated2015
- Employees7.00
- LocationAppili Therapeutics Inc#21-1344 Summer StreetHALIFAX B3H 0A8CanadaCAN
- Phone+1 (902) 442-4655
- Fax+1 (902) 442-4655
- Websitehttps://appilitherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hemostemix Inc | 0.00 | -1.70m | 3.48m | -- | -- | -- | -- | -- | -0.0189 | -0.0189 | 0.00 | -0.09 | 0.00 | -- | -- | -- | -571.80 | -599.98 | -- | -- | -- | -- | -- | -- | -- | -2.45 | -- | -- | -- | -- | 52.21 | -- | -- | -- |
Quest PharmaTech Inc | 0.00 | 12.69m | 4.23m | 0.00 | 0.3332 | 0.1898 | 0.3332 | -- | 0.075 | 0.075 | 0.00 | 0.1318 | 0.00 | -- | -- | -- | 50.73 | 7.62 | 53.01 | 8.45 | -- | -- | -- | -- | -- | -- | 0.043 | 0.00 | -- | -- | 95.35 | -- | -- | -- |
Appili Therapeutics Inc | 827.41k | -3.78m | 4.85m | 7.00 | -- | -- | -- | 5.86 | -0.0312 | -0.0312 | 0.0068 | -0.0901 | 0.358 | -- | 1.54 | 118,201.40 | -163.58 | -128.44 | -- | -251.87 | -- | -- | -456.96 | -2,103.81 | -- | -5.20 | -- | -- | 147.59 | -- | 59.09 | -- | 17.59 | -- |
StageZero Life Sciences Ltd | -100.00bn | -100.00bn | 4.92m | 40.00 | -- | -- | -- | -- | -- | -- | -- | -0.1142 | -- | -- | -- | -- | -- | -135.76 | -- | -- | -- | -2.74 | -- | -246.92 | 0.0176 | -- | -- | -- | -25.12 | 55.93 | -52.53 | -- | -- | -- |
Marvel Biosciences Corp | 0.00 | -2.10m | 4.97m | -- | -- | -- | -- | -- | -0.0529 | -0.0529 | 0.00 | -0.0693 | 0.00 | -- | -- | -- | -268.48 | -- | -- | -- | -- | -- | -- | -- | -- | -14.33 | -- | -- | -- | -- | 10.29 | -- | -- | -- |
Innovotech Inc | 1.24m | -176.78k | 5.46m | 16.00 | -- | 6.58 | -- | 4.40 | -0.0045 | -0.0045 | 0.0319 | 0.0213 | 1.13 | 6.10 | 7.97 | -- | -16.10 | 2.90 | -19.15 | 3.56 | 69.63 | 71.56 | -14.25 | 2.19 | 2.24 | -- | 0.00 | -- | 5.05 | 7.42 | -15.43 | -- | 35.69 | -- |
Principal Technologies Inc | 618.64k | -1.90m | 5.53m | -- | -- | 9.11 | -- | 8.94 | -0.0766 | -0.0766 | 0.0246 | 0.0165 | 0.5664 | -- | 2.92 | -- | -170.72 | -- | -445.11 | -- | 21.57 | -- | -301.45 | -- | -- | -31.95 | 0.0959 | -- | 25.43 | -- | 23.53 | -- | -- | -- |
Rakovina Therapeutics Inc | 0.00 | -2.72m | 7.01m | -- | -- | 2.38 | -- | -- | -0.039 | -0.039 | 0.00 | 0.042 | 0.00 | -- | -- | -- | -53.46 | -- | -56.12 | -- | -- | -- | -- | -- | -- | -16.52 | 0.3151 | -- | -- | -- | 6.39 | -- | -- | -- |
XORTX Therapeutics Inc | 0.00 | -4.63m | 7.20m | 3.00 | -- | 2.09 | -- | -- | -1.94 | -1.94 | 0.00 | 1.19 | 0.00 | -- | -- | -- | -42.59 | -35.42 | -45.30 | -40.37 | -- | -- | -- | -- | -- | -- | 0.0056 | -- | -- | -- | 72.04 | -- | 7.91 | -- |